- Home
- SILA vs COLL Comparison
SILA vs COLL Comparison
Compare SILA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILA
- COLL
- Stock Information
- Founded
- SILA 2013
- COLL 2002
- Country
- SILA United States
- COLL United States
- Employees
- SILA N/A
- COLL N/A
- Industry
- SILA
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SILA
- COLL Health Care
- Exchange
- SILA NYSE
- COLL Nasdaq
- Market Cap
- SILA 1.2B
- COLL 1.1B
- IPO Year
- SILA N/A
- COLL 2015
- Fundamental
- Price
- SILA $24.42
- COLL $29.58
- Analyst Decision
- SILA Strong Buy
- COLL Strong Buy
- Analyst Count
- SILA 3
- COLL 6
- Target Price
- SILA $29.00
- COLL $42.00
- AVG Volume (30 Days)
- SILA 450.8K
- COLL 440.1K
- Earning Date
- SILA 11-12-2024
- COLL 11-07-2024
- Dividend Yield
- SILA 6.54%
- COLL N/A
- EPS Growth
- SILA N/A
- COLL 757.11
- EPS
- SILA 0.37
- COLL 2.16
- Revenue
- SILA $186,225,000.00
- COLL $599,245,000.00
- Revenue This Year
- SILA N/A
- COLL $13.02
- Revenue Next Year
- SILA N/A
- COLL $18.01
- P/E Ratio
- SILA $66.09
- COLL $13.68
- Revenue Growth
- SILA N/A
- COLL 9.62
- 52 Week Low
- SILA $20.20
- COLL $25.07
- 52 Week High
- SILA $26.50
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SILA N/A
- COLL 26.96
- Support Level
- SILA N/A
- COLL $29.69
- Resistance Level
- SILA N/A
- COLL $35.62
- Average True Range (ATR)
- SILA 0.00
- COLL 1.41
- MACD
- SILA 0.00
- COLL -0.39
- Stochastic Oscillator
- SILA 0.00
- COLL 6.36
About SILA SILA REALTY TRUST INC
Sila Realty Trust Inc is a real estate investment trust. Its investment objective is to pay regular cash distributions to stockholders and to preserve, protect, and return capital contributions to stockholders. The company owns and manages healthcare assets. The company generates revenue from real estate investments in healthcare properties.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.